Literature DB >> 23376456

Increased cytotoxic capacity of tumor antigen specific human T cells after in vitro stimulation with IL21 producing dendritic cells.

A W Turksma1, H J Bontkes, J J Ruizendaal, H van den Heuvel, K B J Scholten, S J A M Santegoets, T D de Gruijl, C J L M Meijer, E Hooijberg.   

Abstract

Monocyte derived dendritic cells (moDC) electroporated with tumor associated antigen derived mRNA can elicit specific T cells against tumor cells in vivo. IL21 has been shown to enhance activation and cytotoxicity in CD8+ T cells. We therefore investigated in vitro effects on human CD8+ T-cells after stimulation with IL21 mRNA electroporated moDC. Codon modification of the IL21 gene significantly enhanced IL21 production upon electroporation of moDC. Tumor associated antigen specific CTL induction efficiency was significantly enhanced when codon modified IL21 mRNA was co-electroporated with tumor associated antigen mRNA. Tumor associated antigen specific T cells induced by codon modified IL21-DC demonstrated increased cytotoxic capacity and killing compared to control cultures. In conclusion, ectopic expression of codon modified IL21 by moDC enhances the priming efficiency of the DC as well as the cytotoxic potential of the induced CTL.
Copyright © 2013 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23376456     DOI: 10.1016/j.humimm.2013.01.014

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  6 in total

1.  Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization.

Authors:  Caroline Aspord; Laetitia Tramcourt; Claire Leloup; Jean-Paul Molens; Marie-Therese Leccia; Julie Charles; Joel Plumas
Journal:  J Invest Dermatol       Date:  2014-04-21       Impact factor: 8.551

Review 2.  Understanding the biology of antigen cross-presentation for the design of vaccines against cancer.

Authors:  Cynthia M Fehres; Wendy W J Unger; Juan J Garcia-Vallejo; Yvette van Kooyk
Journal:  Front Immunol       Date:  2014-04-08       Impact factor: 7.561

3.  Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo.

Authors:  Daphné Benteyn; Sébastien Anguille; Sandra Van Lint; Carlo Heirman; An Mt Van Nuffel; Jurgen Corthals; Sebastian Ochsenreither; Wim Waelput; Katrien Van Beneden; Karine Breckpot; Viggo Van Tendeloo; Kris Thielemans; Aude Bonehill
Journal:  Mol Ther Nucleic Acids       Date:  2013-11-19       Impact factor: 10.183

4.  Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients.

Authors:  Annelies W Turksma; Hetty J Bontkes; Janneke J Ruizendaal; Kirsten B J Scholten; Johanneke Akershoek; Shakila Rampersad; Laura M Moesbergen; Saskia A G M Cillessen; Saskia J A M Santegoets; Tanja D de Gruijl; C René Leemans; Chris J L M Meijer; Erik Hooijberg
Journal:  J Transl Med       Date:  2013-06-20       Impact factor: 5.531

5.  IL-21 in cancer immunotherapy: At the right place at the right time.

Authors:  Saskia Jam Santegoets; Annelies W Turksma; Daniel J Powell; Erik Hooijberg; Tanja D de Gruijl
Journal:  Oncoimmunology       Date:  2013-04-16       Impact factor: 8.110

6.  Predicting combinations of immunomodulators to enhance dendritic cell-based vaccination based on a hybrid experimental and computational platform.

Authors:  Rita Ahmed; Isaac Crespo; Sandra Tuyaerts; Amel Bekkar; Michele Graciotti; Ioannis Xenarios; Lana E Kandalaft
Journal:  Comput Struct Biotechnol J       Date:  2020-08-08       Impact factor: 7.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.